Pontali E., Raviglione M. C., Migliori G. B., Akkerman O. W., Alffenaar J. W., Blanc F. X., Borisov S., Cirillo D. M., Dalcolmo M., Dheda K., Kritski A. L., Lienhardt Christian, Olliaro P., Tadolini M., Tiberi S., Udwadia Z., Global T. B. Network Clinical Trials. (2019). Regimens to treat multidrug-resistant tuberculosis : past, present and future perspectives. European Respiratory Review, 28 (152), p. art. 190035 [7 p.]. ISSN 0905-9180.
Titre du document
Regimens to treat multidrug-resistant tuberculosis : past, present and future perspectives
Année de publication
2019
Auteurs
Pontali E., Raviglione M. C., Migliori G. B., Akkerman O. W., Alffenaar J. W., Blanc F. X., Borisov S., Cirillo D. M., Dalcolmo M., Dheda K., Kritski A. L., Lienhardt Christian, Olliaro P., Tadolini M., Tiberi S., Udwadia Z., Global T. B. Network Clinical Trials
Source
European Respiratory Review, 2019,
28 (152), p. art. 190035 [7 p.] ISSN 0905-9180
Over the past few decades, treatment of multidrug-resistant (MDR)/ extensively drugresistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 2024 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9-10 months. The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.
Plan de classement
Santé : généralités [050]
Localisation
Fonds IRD [F B010076505]
Identifiant IRD
PAR00019680
